A new treatment to prevent scarring in the cornea
Official title: A single dose anti-scarring therapeutic for the cornea
Funded at Dub Therapeutics INC. · NIH-11099032 · Data updated 2026-11-12
This study is testing a new eye drop treatment that aims to prevent and heal corneal scarring, helping to protect your vision from damage caused by injuries or infections.
Quick facts
| Grant type | Sbir 2 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Dub Therapeutics INC. NIH-funded |
| Lab location | 1 site (Syracuse, United States) |
| Project start | September 30, 2023 |
| Project end | July 1, 2025 |
| Funding year | 2024 |
| Award (this year) | $182,000 |
| NIH project number | 3R44EY035188-02S1 |
| Project ID | NIH-11099032 on NIH RePORTER |
Who could benefit from this research
✓Could help
Ideal candidates for this research are individuals who have experienced corneal injuries or infections that may lead to scarring.
✕Less likely to help
Patients with pre-existing severe corneal opacification that has already resulted in significant vision loss may not benefit from this research.
What this research studies
This research focuses on developing a therapeutic approach to prevent and treat corneal scarring, which can severely impair vision. The method involves using a specially designed self-delivery siRNA that targets a specific protein involved in the scarring process. Patients will receive this treatment through eye drops, which deliver the therapeutic directly to the cornea without the need for complex delivery systems. The goal is to reduce the risk of irreversible vision loss due to corneal opacification caused by injury or infection.
Why it matters
Potential benefit: If successful, this research could significantly improve vision preservation for patients at risk of corneal scarring.
How similar studies have gone: While the approach of using siRNA for corneal treatment is innovative, similar strategies targeting fibrotic responses have shown promise in other areas of medicine.
Where this research is happening
-
Dub Therapeutics INC.
Syracuse, United States Active
Researchers
- Principal investigator: Williams, Tere M. — Dub Therapeutics INC.
- Study coordinator: Williams, Tere M.
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page.